Vaxcyte, Inc. (PCVX) Financial Statements
Free cash flow over the same period: -$921.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PCVXVaxcyte, Inc.Follow PCVX — free
—
Price chart with a free account
- Market cap
- 9.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Research & development | 0.07 | 0.08 | 0.17 | 0.33 | 0.48 | 0.79 | 1.03 | |
| Operating income | -0.09 | -0.10 | -0.23 | -0.47 | -0.57 | -0.92 | -1.17 | |
| Pre-tax income | -0.09 | -0.10 | -0.22 | -0.40 | -0.46 | -0.77 | -1.06 | |
| Income tax | — | — | — | — | — | 0.00 | 0.00 | |
| Net income | -0.09 | -0.10 | -0.22 | -0.40 | -0.46 | -0.77 | -1.06 | |
| Diluted EPS ($) | -3.02 | -1.93 | -3.44 | -4.14 | -3.80 | -5.63 | -7.63 | |
| Diluted shares (bn) | — | — | 0.065 | 0.097 | 0.122 | 0.136 | — |
USD billions · SEC XBRL
Vaxcyte, Inc. — questions
- What is Vaxcyte, Inc.'s net income?
- -$1.1B over the twelve months to 2026-06-30.
- What is Vaxcyte, Inc.'s free cash flow?
- -$921.1M over the twelve months to 2026-06-30.
- What are Vaxcyte, Inc.'s diluted earnings per share?
- $-7.63 over the twelve months to 2026-06-30.
Every figure on this page comes from Vaxcyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.